BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In this multicenter study, we investigated the prognostic significance of patient baseline characteristics and EMR markers, as well as evaluated the ability of BCR-ABL1 kinetics to predict outcome in our cohort of 476 first-line imatinib-treated CML patients.